Week of Sep 5–11, 2026

Weekly GLP-1 trial and regulatory updates

Read the public weekly current-awareness feed for changes across GLP-1 and related obesity-drug trials, results, regulatory events, and industry news. Three trial drill-downs are free. Deeper trial drill-down is available with the Plus tier. For focused analysis and context, read the GLP-1 Observer newsletter ↗

New to the mechanism classes? See the GLP-1 Field Guides for plain-English explainers on mono, dual, triple, and combination incretin drugs.

This Week's Highlights

  • Novo Nordisk's semaglutide reduces pediatric BMI in Phase 3 STEP Young trial↗Results
  • Structure Therapeutics reports positive data for oral GLP-1 aleniglipron and amylin-calcitonin agonist ACCG-2671↗News
  • Novo Nordisk begins recruiting pediatric Phase 3 CagriSema Type 2 diabetes trial↗Trial Changes
  • Gan&Lee doses first participant in Phase 1 trial of once-weekly oral GLP-1 GZC8072↗News
  • United Bio-Technology registers 150-patient Phase 3 trial of triple agonist UBT251 in obstructive sleep apnea↗New Trial

Detailed Updates

Click an NCT badge to open the trial detail drawer.
Phase 3ENDPOINT METNovo Nordisk announces positive topline results from STEP Young phase 3 trial of semaglutide in children with obesity
Novo Nordisk announced positive topline results from the STEP Young phase 3 trial, showing 40.4% of obese children aged 6 to under 12 achieved a BMI below the obesity threshold at 68 weeks with semaglutide versus 0% on placebo.
Phase 3Amylin + GLP-1AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
Novo Nordisk A/S
Status: RECRUITING → ACTIVE_NOT_RECRUITING
Phase 3Amylin + GLP-1GLP-1 MonoA Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Novo Nordisk A/S
Status: NOT_YET_RECRUITING → RECRUITING
Phase 2GLP-1/GIP DualA Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Eli Lilly and Company
Status: ACTIVE_NOT_RECRUITING → COMPLETED
Also: PrimaryCompletionDateChanged (-57 days); CompletionDateChanged (-63 days)
Phase 2GLP-1 OtherA Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
Boehringer Ingelheim
Status: RECRUITING → ACTIVE_NOT_RECRUITING
Phase 2Amylin + GLP-1GLP-1 MonoA Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Novo Nordisk A/S
Status: ACTIVE_NOT_RECRUITING → COMPLETED
Also: PrimaryCompletionDateChanged (-56 days)
Phase 2Amylin MonoEfficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Zealand Pharma
Status: ACTIVE_NOT_RECRUITING → COMPLETED
Phase 2GLP-1 MonoEfficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
Kailera
Status: RECRUITING → ACTIVE_NOT_RECRUITING
Phase 1GLP-1 MonoA Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity
Innovent Biologics Technology Limited (Shanghai R&D Center)
Status: RECRUITING → COMPLETED
Phase 1Amylin + GLP-1GLP-1 MonoA Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
Novo Nordisk A/S
Status: RECRUITING → ACTIVE_NOT_RECRUITING
Phase 1Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity
Amgen
Status: RECRUITING → ACTIVE_NOT_RECRUITING
Phase 1GLP-1 MonoA Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants
Hoffmann-La Roche
Status: RECRUITING → ACTIVE_NOT_RECRUITING
First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA
Gan&Lee Pharmaceuticals has dosed the first participant in a Phase 1 safety and tolerability study evaluating GZC8072, an ultra-long-acting once-weekly oral peptide GLP-1 receptor agonist.
Source ↗
Phase 3Triple AgonistUBT251 Injection Phase â…¢ Study (OSA-PAP)
The United Bio-Technology (Hengqin) Co., Ltd. · 150 participants · UNISHAPE-OSA-2
The United Bio-Technology registered a 150-patient Phase 3 trial evaluating UBT251 injection in patients with obstructive sleep apnea (OSA-PAP).
Phase 1/Phase 2Amylin MonoFirst-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671
Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics · 164 participants
Structure Therapeutics has registered a 164-patient Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and food effect of its DACRA candidate ACCG-2671.
Phase 2GLP-1 MonoA Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)
Beijing QL Biopharmaceutical Co.,Ltd · 210 participants
Beijing QL Biopharmaceutical launched a 210-patient Phase 2 trial to evaluate the safety and tolerability of switching adults with obesity from semaglutide to zovaglutide.
Phase 1Amylin + GLP-1A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obesity
Novo Nordisk A/S · 320 participants
Novo Nordisk registered a 320-patient Phase 1 pharmacokinetic study assessing the effects of meal timing and water volume on zenagamtide absorption in individuals with overweight or obesity.
Phase 1A Study of IBI3046 in Participants With Overweight or Obesity
Innovent Biologics (Suzhou) Co. Ltd. · 128 participants
Innovent Biologics registered a 128-patient Phase 1 study evaluating candidate IBI3046 in participants with overweight or obesity.
Phase 1A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Eli Lilly and Company · 184 participants
Eli Lilly initiated a 184-participant Phase 1 study for candidate LY4329090 in otherwise healthy individuals with obesity or overweight.
Phase 1Amylin MonoA Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight
Eli Lilly and Company · 34 participants
Eli Lilly registered a 34-patient Phase 1 study to evaluate eloralintide (LY3841136) in female participants with obesity or overweight.
Phase 1Triple AgonistA Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment
Fujian Shengdi Pharmaceutical Co., Ltd. · 32 participants
Fujian Shengdi Pharmaceutical registered a 32-patient Phase 1 pharmacokinetic study of HRS-4729 injection in healthy participants and patients with renal impairment.
Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification
Novo Nordisk reported positive topline data from the pediatric Phase 3 STEP Young trial of semaglutide, where 40.4% of children aged 6 to under 12 achieved a BMI below the obesity threshold after 68 weeks.
Also covered by: fierce_pharma
Source ↗
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
Structure Therapeutics reported positive clinical data, showing an up to 16.2% weight reduction at 72 weeks for oral GLP-1 aleniglipron and a 3.3% weight reduction in a single-dose study of amylin analog ACCG-2671.
Also covered by: biospace
Source ↗